Recent Publications
Slight-Webb S, Thomas K, Smith M, Wagner CA, Macwana S, Bylinska A, Donato M, Dvorak M, Chang SE, Kuo A, Cheung P, Kalesinskas L, Ganesan A, Dermadi D, Guthridge CJ, DeJager W, Wright C, Foecke MH, Merrill JT, Chakravarty E, Arriens C, Maecker HT, Khatri P, Utz PJ, James JA, Guthridge JM. Ancestry-based differences in the immune phenotype are associated with lupus activity. JCI Insight. 2023 August, PMID: 37606045
Guthridge JM, Wagner CA, James JA. The promise of precision medicine in rheumatology. Nat Med, 2022 July, PMID: 35788174, PMCID: PMC9513842
Munroe ME, Young KA, Guthridge JM, Kamen DL, Gilkeson GS, Weisman MH, Ishimori ML, Wallace DJ, Karp DR, Harley JB, Norris JM, James JA. Pre-Clinical Autoimmunity in Lupus Relatives: Self-Reported Questionnaires and Immune Dysregulation Distinguish Relatives Who Develop Incomplete or Classified Lupus From Clinically Unaffected Relatives and Unaffected, Unrelated Individuals. Front Immunol 13:866181, 2022 June, PMID: 35720322, PMCID: PMC9203691
Wood RA, Guthridge L, Thurmond E, Guthridge CJ, Kheir JM, Bourn RL, Wagner CA, Chen H, DeJager W, Macwana SR, Kamp S, Lu R, Arriens C, Chakravarty EF, Thanou A, Merrill JT, Guthridge JM, James JA. Serologic markers of Epstein-Barr virus reactivation are associated with increased disease activity, inflammation, and interferon pathway activation in patients with systemic lupus erythematosus. J Transl Autoimmun 4:100117, 2021 August, PMID: 35005588, PMCID: PMC8716608
Selected Publications
James JA, Guthridge JM, Chen H, Lu R, Bourn RL, Bean K, Munroe ME, Smith M, Chakravarty E, Baer AN, Noaiseh G, Parke A, Boyle K, Keyes-Elstein L, Coca A, Utset T, Genovese MC, Pascual V, Utz PJ, Holers VM, Deane KD, Sivils KL, Aberle T, Wallace DJ, McNamara J, Franchimont N, St Clair EW. Unique Sjögren’s syndrome patient subsets defined by molecular features. Rheumatology (Oxford). 2020 Apr 1;59(4):860-868. doi: 10.1093/rheumatology/kez335. PubMed PMID: 31497844; PubMed Central PMCID: PMC7188221.
Guthridge JM, Lu R, Tran LT, Arriens C, Aberle T, Kamp S, Munroe ME, Dominguez N, Gross T, DeJager W, Macwana SR, Bourn RL, Apel S, Thanou A, Chen H, Chakravarty EF, Merrill JT, James JA. Adults with systemic lupus exhibit distinct molecular phenotypes in a cross-sectional study. EClinicalMedicine. 2020 Mar;20:100291. doi: 10.1016/j.eclinm.2020.100291. eCollection 2020 Mar. PubMed PMID: 32154507; PubMed Central PMCID: PMC7058913.
Jog NR, McClain MT, Heinlen LD, Gross T, Towner R, Guthridge JM, Axtell RC, Pardo G, Harley JB, James JA. Epstein Barr virus nuclear antigen 1 (EBNA-1) peptides recognized by adult multiple sclerosis patient sera induce neurologic symptoms in a murine model. J Autoimmun. 2020 Jan;106:102332. doi: 10.1016/j.jaut.2019.102332. Epub 2019 Sep 9. PubMed PMID: 31515129; PubMed Central PMCID: PMC6930324.
Slight-Webb S, Guthridge JM, Chakravarty EF, Chen H, Lu R, Macwana S, Bean K, Maecker HT, Utz PJ, James JA. Mycophenolate mofetil reduces STAT3 phosphorylation in systemic lupus erythematosus patients. JCI insight. 2019;4(2). Epub 2019/01/25. doi: 10.1172/jci.insight.124575. PubMed PMID: 30674728; PMCID: PMC6413783.
Lu R, Guthridge JM, Chen H, Bourn RL, Kamp S, Munroe ME, Macwana SR, Bean K, Sridharan S, Merrill JT, James JA. Immunologic findings precede rapid lupus flare after transient steroid therapy. Scientific Reports. 2019;9(1):8590. Epub 2019/06/15. doi: 10.1038/s41598-019-45135-w. PubMed PMID: 31197240.
Jog NR, Young KA, Munroe ME, Harmon MT, Guthridge JM, Kelly JA, Kamen DL, Gilkeson GS, Weisman MH, Karp DR, Gaffney PM, Harley JB, Wallace DJ, Norris JM, James JA. Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals. Annals of the Rheumatic Diseases. 2019. Epub 2019/06/21. doi: 10.1136/annrheumdis-2019-215361. PubMed PMID: 31217170.
James JA, Chen H, Young KA, Bemis EA, Seifert J, Bourn RL, Deane KD, Demoruelle MK, Feser M, O’Dell JR, Weisman MH, Keating RM, Gaffney PM, Kelly JA, Langefeld CD, Harley JB, Robinson W, Hafler DA, O’Connor KC, Buckner J, Guthridge JM, Norris JM, Holers VM. Latent autoimmunity across disease-specific boundaries in at-risk first-degree relatives of SLE and RA patients. EBioMedicine. 2019;42:76-85. Epub 2019/04/07. doi: 10.1016/j.ebiom.2019.03.063. PubMed PMID: 30952617; PMCID: PMC6491794.
Kheir JM, Guthridge CJ, Johnston JR, Adams LJ, Rasmussen A, Gross TF, Munroe ME, Bourn RL, Sivils KL, Guthridge JM, Weisman MH, Wallace DJ, Anaya JM, Rojas Villarraga A, Jarvis JN, Harley JB, James JA. Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus. Lupus Science & Medicine. 2018;5(1):e000247. Epub 2018/03/14. doi: 10.1136/lupus-2017-000247. PubMed PMID: 29531773; PMCID: PMC5844376.
Jog NR, Chakravarty EF, Guthridge JM, James JA. Epstein Barr Virus Interleukin 10 Suppresses Anti-inflammatory Phenotype in Human Monocytes. Frontiers in Immunology. 2018;9:2198. Epub 2018/10/26. doi: 10.3389/fimmu.2018.02198. PubMed PMID: 30356670; PMCID: PMC6189329.
Munroe ME, Young KA, Kamen DL, Guthridge JM, Niewold TB, Costenbader KH, Weisman MH, Ishimori ML, Wallace DJ, Gilkeson GS, Karp DR, Harley JB, Norris JM, James JA. Discerning Risk of Disease Transition in Relatives of Systemic Lupus Erythematosus Patients Utilizing Soluble Mediators and Clinical Features. Arthritis & Rheumatology (Hoboken, NJ). 2017;69(3):630-42. Epub 2016/11/20. doi: 10.1002/art.40004. PubMed PMID: 27863174; PMCID: PMC5329053.